References
- Xiao X, Garbitt CC, Hornicek F, et al. Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. Cancer Treat Rev. 2018;63:61–70.
- Heidenreich O. Targeting oncogenes with siRNAs. Methods Mol Biol. 2009;487:221–242.
- Perry JA, Seong BKA, Stegmaier K. Biology and therapy of dominant fusion oncoproteins involving transcription factor and chromatin regulators in sarcomas. Ann Rev Cancer Biol. 2019; 3:299–321.
- Gaspar N, Di Giannatale A, Geoerger B, et al. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012; 2012:301975.
- Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing’s sarcoma. Oncogene. 2010 Dec;29(32):4504–4516.
- Nakano K, Takahashi S. Translocation-related sarcomas. Int J Mol Sci. 2018; 19(12). E3784.
- Grünewald Tgp, Cidre-Aranaz F, Surdez D et al. Ewing sarcoma. Nat Rev Dis Primers. 2018; 4(1):5.
- Skapek SX, Ferrari A, Gupta AA et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019; 5(1):1.
- Mora J, Modak S, Cheung NK, et al. Desmoplastic small round cell tumor 20 years after its discovery. Future Oncol. 2015;11(7):1071–1081.
- Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015;5(2):124–134.
- Renzi S, Anderson ND, Light N, et al. Ewing-like sarcoma: an emerging family of round cell sarcomas. J Cell Physiol. 2019;234(6):7999–8007.
- Saikia T. The cure of chronic Myeloid Leukemia: are we there yet? Curr Oncol Rep. 2018; 20(2):12.
- Mateo-Lozano S, Gokhale PC, Soldatenkov VA, et al. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing’s sarcoma. Clin Cancer Res. 2006;12(22):6781–9790.
- Bernasconi M, Remppis A, Fredericks WJ, et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A. 1996;93(23):13164–13169.
- Kovar H, Ban J, Pospisilova S. Potentials for RNAi in sarcoma research and therapy: ewing’s sarcoma as a model. Semin Cancer Biol. 2003;13(4):275–281.
- Kikuchi K, Tsuchiya K, Otabe O, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 2008;365(3):568–574.
- Peng C, Zhao H, Chen W, et al. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma. Oncotarget. 2016;7(41):66822–66834.
- Pandey PR, Chatterjee B, Olanich ME, et al. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. J Pathol. 2017;241(5):626–637.
- Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med. 2011;17(3):290–291.
- Grosso, F., Sanfilippo, R., Virdis, E., Piovesan, C., Collini, P., Dileo, P. et al, Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009; 20:1439–1444.
- Le Cesne, A., Blay, J.-Y., Judson, I., Van Oosterom, A., Verweij, J., Radford, J. et al, Phase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005; 23:576–584.
- Demetri, G.D., von Mehren, M., Jones, R.L., Hensley, M.L., Schuetze, S.M., Staddon, A. et al, Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2015; 34:786–793.
- Laporte AN, Poulin NM, Barrott JJ, et al. Death by HDAC inhibition in synovial sarcoma cells. Mol Cancer Ther. 2017;16(12):2656–2667.
- Rello-Varona S, Tirado OM. DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma. Pharmacogenomics. 2017;18(14):1307–1309.
- Franzetti GA, Laud-Duval K, van der Ent W, et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene. 2017;36(25):3505–3514.